Stockreport

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta [Seeking Alpha]

Vir Biotechnology, Inc.  (VIR) 
PDF Initial data from the SOLSTICE trial in patients with Hepatitis Delta treated with elebsiran and tobevibart showed promising results. The company plans to report addi [Read more]